<template>
	<div class="grid grid-cols-1 grid-rows-1 pb-6 relative z-10 h-full">
		<div
			class="flex flex-col justify-center font-effra transition-all duration-300"
			:class="[sidebarOpen ? 'ml-[124px]' : 'ml-[224px]']"
		>
			<div>
				<h1 class="text-[32px] font-bold text-electric-blue leading-normal max-w-[920px]">
					Exblifep<sup>®</sup> is where microbiological eradication* meets efficacy<sup>1</sup>
				</h1>
				<img
					src="/lime-green-border.png"
					alt="Lime Green Border"
					class="h-1.5 w-[300px] my-5"
				/>
			</div>
			<section class="grid grid-cols-2 bg-white py-6 px-8 text-xl text-cool-grey gap-y-10 gap-x-20 max-w-[1380px]">
				<div class="flex gap-x-7 items-center col-span-2">
					<img
						src="/summary-icon-1.png"
						alt="Summary Icon 1"
						class="w-[130px] h-[130px]"
					/>
					<div class="min-w-[3px] h-[66px] bg-dark-blue"></div>
					<p>
						EXBLIFEP<sup>®</sup> is indicated for the
						<span class="text-dark-blue font-bold"
							>treatment of adult patients with cUTI including AP, HAP/VAP and bacteraemia associated with these infections,</span
						>
						caused by gram-negative bacteria<sup>5</sup>
					</p>
				</div>
				<div class="flex gap-x-7 items-center">
					<img
						src="/summary-icon-2.png"
						alt="Summary Icon 2"
						class="w-[130px] h-[130px]"
					/>
					<div class="min-w-[3px] h-[66px] bg-dark-blue"></div>
					<p>
						EXBLIFEP<sup>®</sup> demonstrated
						<span class="text-dark-blue font-bold">non-inferiority and superiority vs piperacillin/tazobactam</span> in the composite endpoint of
						clinical cure and microbiological eradication in adults with cUTIs at Day 14 in the Primary Analysis Set?<sup>†1</sup>
					</p>
				</div>
				<div class="flex gap-x-7 items-center">
					<img
						src="/summary-icon-3.png"
						alt="Summary Icon 3"
						class="w-[130px] h-[130px]"
					/>
					<div class="min-w-[3px] h-[66px] bg-dark-blue"></div>
					<p>
						EXBLIFEP<sup>®</sup> is indicated to treat HAP/VAP, and
						<span class="text-dark-blue font-bold">could be a useful carbapenem-sparing option for ESBL-producing pathogens<sup>5,9</sup></span>
					</p>
				</div>
				<div class="flex gap-x-7 items-center">
					<img
						src="/summary-icon-4.png"
						alt="Summary Icon 4"
						class="w-[130px] h-[130px]"
					/>
					<div class="min-w-[3px] h-[66px] bg-dark-blue"></div>
					<p>
						EXBLIFEP<sup>®</sup> demonstrated <span class="text-dark-blue font-bold">high intrapulmonary penetration</span> and similar distribution
						kinetics of both compounds into the ELF, supporting its use in the treatment of HAP/VAP<sup>6,10</sup>
					</p>
				</div>
				<div class="flex gap-x-7 items-center">
					<img
						src="/summary-icon-5.png"
						alt="Summary Icon 5"
						class="w-[130px] h-[130px]"
					/>
					<div class="min-w-[3px] h-[66px] bg-dark-blue"></div>
					<p>
						EXBLIFEP<sup>®</sup> demonstrated a
						<span class="text-dark-blue font-bold">favourable overall safety profile, comparable to</span> piperacillin tazobactam<sup>1</sup>
					</p>
				</div>
			</section>

			<section class="max-w-[1380px] bg-[#00EAFF] shadow-dark py-4 flex items-center mt-9 relative z-10 border-[6px] border-white">
				<div class="pl-9 pr-7 py-3 border-r-[3px] border-[#002470]">
					<img
						src="/chevron-right-bleu.png"
						alt="Chevron Right Bleu"
						class="w-[64px] h-[64px] mr-7"
					/>
				</div>
				<h2 class="pl-10 text-2xl font-bold text-[#002470] max-w-[1200px]">
					At ADVANZ PHARMA, we are committed to taking your treatment options further to improve patient lives, by providing novel therapeutic options
					in the fight against gram-negative and gram-positive infections
				</h2>
			</section>
		</div>
		<footer class="flex flex-col">
			<the-footer
				class="transition-all duration-300 max-w-[1380px]"
				:class="[sidebarOpen ? 'ml-[124px]' : 'ml-[224px]']"
			>
				AMR, antimicrobial resistance; AP, acute pyelonephritis; CFU, colony-forming unit; cUTI, complicated urinary tract infection; ELF, epithelial
				lining fluid; HAP/VAP, hospital-acquired pneumonia/ventilator associated pneumonia; MIC, minimum inhibitory concentration.<br />
				*In the ALLIUM study, microbiological eradication is defined as &lt; 103 CFU/mL of qualifying baseline pathogen in urine.<sup>1</sup><br />
				†Primary outcome was the proportion of patients in the primary analysis set (PAS) who achieved a composite outcome of complete resolution of the
				baseline signs and symptoms present at screening (clinical cure) and reduction of qualifying baseline pathogen to less than 103 CFU/mL in urine
				(microbiological eradication) at Day 14. The PAS included all patients who received at least 1 dose of study drug and had a gram-negative
				baseline pathogen in urine at 105 CFU/mL or more or the same pathogen present in both blood and urine cultures that was not resistant to either
				cefepime/enmetazobactam (MIC ≤ 8 μg/mL) or piperacillin/tazobactam (MIC ≤ 64 μg/mL).<sup>1</sup>
			</the-footer>
			<div class="flex justify-between items-center mt-4 mr-12">
				<ExploreAnother />
			</div>
		</footer>
	</div>
</template>

<script setup>
import TheFooter from '../components/exblifep/TheFooter.vue';
import NextSection from '../components/exblifep/NextSection.vue';
import ExploreAnother from '../components/exblifep/ExploreAnother.vue';

defineProps({
	sidebarOpen: {
		type: Boolean,
		required: true,
	},
});
</script>
